Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2003
04/08/2003CA2061601C Methods and compositions for the treatment of infection and control of flora
04/08/2003CA2050300C Tnf-inhibiting proteins and the preparation thereof
04/08/2003CA2023810C Pharmaceutical composition
04/08/2003CA2008368C Soluble molecule related to but distinct from icam-1
04/04/2003WO2002030940A2 Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
04/04/2003CA2424926A1 Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
04/03/2003WO2003028001A2 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
04/03/2003WO2003027671A2 Apoptosis
04/03/2003WO2003027639A2 Glucocorticoid receptor nuclear translocation domain
04/03/2003WO2003027637A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
04/03/2003WO2003027327A1 Antisense modulation of interleukin 8 expression
04/03/2003WO2003027319A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes
04/03/2003WO2003027316A2 Methods of using 33751, a human potassium channel family member
04/03/2003WO2003027313A2 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
04/03/2003WO2003027308A2 56294 and 56629, novel human metalloproteases and uses thereof
04/03/2003WO2003027287A1 Kidney-specific urate transporter and gene thereof
04/03/2003WO2003027285A1 Dna sequences for human angiogenesis genes
04/03/2003WO2003027266A2 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
04/03/2003WO2003027265A2 Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027254A2 15625 receptor, a novel g-protein coupled receptor
04/03/2003WO2003027251A2 Novel molecules of the pyrin domain protein family and uses thereof
04/03/2003WO2003027246A2 Antagonists
04/03/2003WO2003027244A2 Antisense oligonucleotides and methods to induce tumor cell death
04/03/2003WO2003027239A2 Melanin-concentrating hormone receptor antagonist binding protein
04/03/2003WO2003027237A2 Method of modulating or examining ku70 levels in cells
04/03/2003WO2003027235A2 Afap sequences, polypeptides, antibodies and methods
04/03/2003WO2003027232A2 Method for producing biologically active products
04/03/2003WO2003027229A2 Antisense modulation of rip2 expression
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027169A1 Material consisting of at least a biodegradable polymer and cyclodextrins
04/03/2003WO2003027147A2 Human coagulation factor vii polypeptides
04/03/2003WO2003027146A1 Use of cardiotrophin in hepatic diseases
04/03/2003WO2003027144A1 ENZYME PHOSPHORYLATING Ser46 OF p53
04/03/2003WO2003027140A2 Identification of s. typhimurium genes by software-based genome comparison
04/03/2003WO2003027113A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027112A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027091A1 Pyrane derivatives as both ace- and nep- inhibitors
04/03/2003WO2003027081A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003026714A1 Porous ceramic composite bone grafts
04/03/2003WO2003026710A1 Mixture for use as a protective dressing
04/03/2003WO2003026709A1 Liquid mixture for use as a dressing spray
04/03/2003WO2003026696A1 Method of controlling proliferation of cancer cells and cell death
04/03/2003WO2003026695A1 Agonists and antagonists of cylixin for the treatment of metabolic disorders
04/03/2003WO2003026693A2 Inhibitors of costimulation by 0x40 and their use against infectious diseases
04/03/2003WO2003026691A2 Use of hmgb1 for the activation of dendritic cells
04/03/2003WO2003026689A1 Autologous growth factor cocktail composition, method of production and use
04/03/2003WO2003026687A1 Delivery system for biological component
04/03/2003WO2003026686A1 Potentiating the therapeutic effects of interferons
04/03/2003WO2003026685A1 Agents improving lipid metabolism in liver
04/03/2003WO2003026684A1 Modulation of physiological processes and agents useful for same
04/03/2003WO2003026675A1 Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
04/03/2003WO2003026669A1 Monobactam antibacterial compounds and methods of use thereof
04/03/2003WO2003026645A1 Tetrapeptide derivative crystals
04/03/2003WO2003026641A2 Modulation of stat activity
04/03/2003WO2003026636A1 Thrombus/thrombogenesis inhibitors
04/03/2003WO2003026635A2 Improved method of treating the syndrome of type 2 diabetes in humans
04/03/2003WO2003026622A1 Lisinopril compositions having large-particle dcpd
04/03/2003WO2003026602A2 Medicine for preventing and treating bromidrosis
04/03/2003WO2003026591A2 Modification of feeding behavior
04/03/2003WO2003026584A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
04/03/2003WO2003026581A2 Pharmaceutical compositions and methods for treating cancer
04/03/2003WO2003026580A2 Interactive therapeutic enclosures
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026575A2 Molecules specific for npff receptors and uses thereof
04/03/2003WO2003026566A2 Atlastin
04/03/2003WO2003026494A2 Galectins-1-and-4 in tumor development
04/03/2003WO2003026492A2 Prevention and treatment of restenosis by local administration of drug
04/03/2003WO2003026490A2 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
04/03/2003WO2003026479A2 Methods of suppressing microglial activation
04/03/2003WO2003026400A2 METABOTROPIC GLUTAMATE RECEPTOR 4B (mGluR4) DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
04/03/2003WO2003026397A2 Thyrotropin releasing hormone receptor disruptions, compositions and methods relating thereto
04/03/2003WO2003011889A3 Antisense modulation of acyl coa cholesterol acyltransferase-2 expression
04/03/2003WO2003011395A3 Method of utilizing neurotrophins to manipulate reproductive capacity
04/03/2003WO2003006104A3 Lymphatic endothelial cells materials and methods
04/03/2003WO2002100337A3 Antithrombotic thrombin variants
04/03/2003WO2002098359A3 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002090585A3 Genetic polymorphism pattern of tgfb1 as marker for susceptability to renal disease
04/03/2003WO2002085286A8 Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
04/03/2003WO2002079437A3 Transgenic mice containing abc transporter-like aptase gene disruptions
04/03/2003WO2002078520A3 IL-1ss INHIBITION FOR MYELOMA AND RELATED DISORDERS
04/03/2003WO2002077161A3 Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses
04/03/2003WO2002077010A3 Method of preventing t-cell mediated responses by map proteins
04/03/2003WO2002073213A3 Assay
04/03/2003WO2002073206A3 Metabolic phenotyping in therapy with anxiolytics
04/03/2003WO2002070694A3 Methods and compositions for modifying a receptor tyrosine kinase/protein tyrosine kinase signal to an apoptotic signal in a cell
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002068465A3 Novel p53-inducible protein
04/03/2003WO2002066513A3 Human circulating lekti fragments hf7072, hf7638 and hf14448 and use thereof
04/03/2003WO2002064097A3 Vegf-d expression in brain cancer
04/03/2003WO2002059256A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
04/03/2003WO2002057421A3 Human tumor necrosis factor receptors tr13 and tr14
04/03/2003WO2002057413A3 Peptides for activation and inhibition of delta pkc
04/03/2003WO2002044328A3 Anti-angiogenic polypeptides
04/03/2003WO2002044211A3 Endozepine like protein, polynucleotide encoding them and methods of using the same
04/03/2003WO2002042444A8 Fungal gene cluster associated with pathogenesis
04/03/2003WO2002040670A3 A human g-protein coupled receptor, hgprbmy8, expressed hig hly in brain
04/03/2003WO2002034248A3 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
1 ... 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 ... 3163